Article Details
Retrieved on: 2021-04-30 22:23:48
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Because Theravance Biopharma is relatively undervalued, the long-term return of its stock is likely to be higher than its business growth, which averaged ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here